[go: up one dir, main page]

DE60223542D1 - Zusammensetzung mit fulvestrant - Google Patents

Zusammensetzung mit fulvestrant

Info

Publication number
DE60223542D1
DE60223542D1 DE60223542T DE60223542T DE60223542D1 DE 60223542 D1 DE60223542 D1 DE 60223542D1 DE 60223542 T DE60223542 T DE 60223542T DE 60223542 T DE60223542 T DE 60223542T DE 60223542 D1 DE60223542 D1 DE 60223542D1
Authority
DE
Germany
Prior art keywords
fulvestrant
composition
oestra
17beta
triene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60223542T
Other languages
English (en)
Other versions
DE60223542T2 (de
Inventor
Paul Richard Gellert
Alison Margaret Potts
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Application granted granted Critical
Publication of DE60223542D1 publication Critical patent/DE60223542D1/de
Publication of DE60223542T2 publication Critical patent/DE60223542T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
DE60223542T 2001-07-07 2002-07-03 Zusammensetzung mit fulvestrant Expired - Lifetime DE60223542T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0116620.6A GB0116620D0 (en) 2001-07-07 2001-07-07 Formulation
GB0116620 2001-07-07
PCT/GB2002/003084 WO2003006063A2 (en) 2001-07-07 2002-07-03 Formulation comprising fulvestrant

Publications (2)

Publication Number Publication Date
DE60223542D1 true DE60223542D1 (de) 2007-12-27
DE60223542T2 DE60223542T2 (de) 2008-11-13

Family

ID=9918096

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60223542T Expired - Lifetime DE60223542T2 (de) 2001-07-07 2002-07-03 Zusammensetzung mit fulvestrant

Country Status (12)

Country Link
US (1) US20040175402A1 (de)
EP (1) EP1409021B1 (de)
JP (1) JP4295087B2 (de)
AT (1) ATE378070T1 (de)
AU (1) AU2002317298A1 (de)
CY (1) CY1107142T1 (de)
DE (1) DE60223542T2 (de)
DK (1) DK1409021T3 (de)
ES (1) ES2294146T3 (de)
GB (1) GB0116620D0 (de)
PT (1) PT1409021E (de)
WO (1) WO2003006063A2 (de)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1627644A4 (de) * 2003-05-23 2012-01-18 Hisamitsu Pharmaceutical Co Zubereitung zur externen perkutanen verabreichung mit einem nichtsteroidalen entzündungshemmenden arzneimittel und einem interleukin-1a-produktionshemmer
CN100571696C (zh) * 2005-01-05 2009-12-23 国防教育研究基金会 尿苷二磷酸-葡萄糖醛酸基转化酵素2b(ugt2b)的抑制剂及促进剂
JP2009509942A (ja) * 2005-09-26 2009-03-12 ホスピラ・オーストラリア・ピーティーワイ・リミテッド フルベストラント製剤
WO2007044662A2 (en) * 2005-10-05 2007-04-19 Sicor, Inc. Separation of fulvestrant isomers
EP2249839A4 (de) 2008-03-07 2013-10-16 Chemwerth Fulvestrantformulierungen
GB0815435D0 (en) * 2008-08-22 2008-10-01 Camurus Ab Formulations
ES2708302T3 (es) 2011-05-20 2019-04-09 Capital Business Y Gestion De Finanzas S L Composición farmacéutica
CN102600064A (zh) * 2012-03-31 2012-07-25 西安力邦制药有限公司 氟维司群或其衍生物缓释制剂及其制备方法
US11179468B2 (en) 2012-04-09 2021-11-23 Eagle Pharmaceuticals, Inc. Fulvestrant formulations
US9271990B2 (en) 2014-02-14 2016-03-01 Fresenius Kabi Usa, Llc Fulvestrant formulations
WO2015157752A1 (en) * 2014-04-11 2015-10-15 Sam Houston State University Dialkyl trisulfides and formulations of dialkyl trisulfides for use as a cyanide antidote
CN108159055A (zh) * 2018-01-04 2018-06-15 西安力邦医药科技有限责任公司 治疗乳腺癌的长效递药系统、其制备方法及应用
CN111465398A (zh) * 2018-01-31 2020-07-28 富士胶片株式会社 注射用制剂的制造方法
CN113694017B (zh) * 2020-05-11 2024-04-02 鲁南制药集团股份有限公司 一种氟维司群注射制剂及其制备方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8813353D0 (en) * 1988-06-06 1988-07-13 Ici Plc Therapeutic product
GB0000313D0 (en) * 2000-01-10 2000-03-01 Astrazeneca Uk Ltd Formulation
GB0008172D0 (en) * 2000-04-05 2000-05-24 Astrazeneca Ab Therapy

Also Published As

Publication number Publication date
JP4295087B2 (ja) 2009-07-15
US20040175402A1 (en) 2004-09-09
PT1409021E (pt) 2008-01-11
DE60223542T2 (de) 2008-11-13
DK1409021T3 (da) 2008-02-11
CY1107142T1 (el) 2012-10-24
ES2294146T3 (es) 2008-04-01
WO2003006063A3 (en) 2003-05-15
AU2002317298A1 (en) 2003-01-29
EP1409021A2 (de) 2004-04-21
GB0116620D0 (en) 2001-08-29
JP2004521151A (ja) 2004-07-15
ATE378070T1 (de) 2007-11-15
WO2003006063A2 (en) 2003-01-23
EP1409021B1 (de) 2007-11-14

Similar Documents

Publication Publication Date Title
CY1107142T1 (el) Τυποποιηση που περιλαμβανει fulvestrant
BG106833A (en) Fulvestrant formulation
IL188774A0 (en) Compositions for delivery of drug combinations
EA200901393A1 (ru) Фармацевтическая композиция, содержащая гестагены и/или эстрогены и 5 метил-(6s)-тетрагидрофолат
HK1077208A1 (en) Topical composition containing at least one vitminD or one vitamin D analogue and at least one cort icosteroid
TR200002299T2 (tr) Epotilon kompozisyonları.
BR0307893A (pt) Formulação oftálmica com sistema de goma
NZ527157A (en) Compositions for delivering bisphosphonates
HK1118202A1 (en) Pharmaceutical compositions of a neuroactive steroid and uses thereof
DE60205749D1 (de) Oral anzuwendende arzneizusammensetzungen mit gesteuerter wirkstoffabgabe
MXPA05008913A (es) Formulacion oftalmica estable que contiene antibiotico y corticoesteroide.
BR0212386A (pt) Composto, formulação farmacêutica, e, uso de um composto
PT1121127E (pt) Composicoes farmaceuticas orais contendo buprenorfina
WO2002015959A3 (en) Compounds and compositions for delivering active agents
NO20064808L (no) Orale matrixformuleringer med licarbazepin
AU2001261516A1 (en) Semi-solid delivery vehicle and pharmaceutical compositions
WO2004004639A3 (en) A novel stable formulation
GT200100063A (es) El uso de composiciones a base de antibioticos de azalidos para tratar o prevenir una infeccion bacteriana o protozoariaen mamiferos
DE60133198D1 (en) Glykopeptidderivate mit carboxysacchariden
AU2369801A (en) Pharmaceutical composition for transdermally administering hormones with an additive that enhances permeation
BR0010499A (pt) Agentes endoparasiticidas
SE9902742D0 (sv) New pharmaceutical formultion
AU2624499A (en) Oral compositions at low dosage of cytotoxic proteins
BRPI0510906A (pt) composição farmacêutica tópica, composição para administração tópica e seu uso
GB0128071D0 (en) Medicament

Legal Events

Date Code Title Description
8364 No opposition during term of opposition